SuperworthSupernus Pharmaceuticals EPS SUPN
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$1.92
- Latest quarter, Q2 FY26
- −$1.01
- −353% on a year earlier
- Fiscal year 2025
- −$0.68
- −152% on the year before
Supernus Pharmaceuticals' earnings per share was −$1.92 over the twelve months to Jun 30, 2026, down 267% on a year earlier.
In its latest quarter, Q2 FY26, it was −$1.01, down 353% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.68 | −152% |
| FY2024 | $1.32 | n/a |
| FY2023 | $0.00 | −100% |
| FY2022 | $1.02 | +4% |
| FY2021 | $0.98 | −58% |
| FY2020 | $2.36 | +12% |
| FY2019 | $2.11 | +2% |
| FY2018 | $2.06 | +94% |
| FY2017 | $1.06 | −38% |
| FY2016 | $1.70 | +507% |
| FY2015 | $0.28 | n/a |
| FY2014 | −$0.27 | n/a |
| FY2013 | −$2.92 | n/a |
| FY2012 | −$7.72 | −126% |
| FY2011 | $30.23 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.01 | −353% | −$1.92 | |
| Q1 FY26 | −$0.04 | n/a | −$0.51 | |
| Q4 FY25 | −$0.07 | −126% | −$0.68 | |
| Q3 FY25 | −$0.80 | −216% | −$0.34 | |
| Q2 FY25 | $0.40 | +11% | $1.15 | |
| Q1 FY25 | −$0.21 | n/a | $1.11 | |
| Q4 FY24 | $0.27 | +1250% | $1.32 | |
| Q3 FY24 | $0.69 | n/a | $1.07 | |
| Q2 FY24 | $0.36 | n/a | $0.09 | |
| Q1 FY24 | $0.00 | −100% | −$0.29 | |
| Q4 FY23 | $0.02 | −95% | $0.00 | |
| Q3 FY23 | −$0.29 | −1067% | $0.40 |
Against its peers
Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SUPNSupernus Pharmaceuticals | −$1.92 | −267% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Supernus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.